Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway

Harshil D. Dhruv, Alison Roos, Patrick J. Tomboc, Serdar Tuncali, Ashley Chavez, Ian Mathews, Michael E. Berens, Joseph C Loftus, Nhan Tran

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most common primary tumor of the CNS and carries a dismal prognosis. The aggressive invasion of GBM cells into the surrounding normal brain makes complete resection impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Median survival for newly diagnosed GBM is 14.6 months and declines to 8 months for patients with recurrent GBM. New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome. We have demonstrated that TROY (TNFRSF19), a member of the TNFR super-family, plays an important role in GBM invasion and resistance. Knockdown of TROY expression inhibits GBM cell invasion, increases sensitivity to temozolomide, and prolongs survival in an intracranial xenograft model. Propentofylline (PPF), an atypical synthetic methylxanthine compound, has been extensively studied in Phase II and Phase III clinical trials for Alzheimer’s disease and vascular dementia where it has demonstrated blood–brain permeability and minimal adverse side effects. Here we showed that PPF decreased GBM cell expression of TROY, inhibited glioma cell invasion, and sensitized GBM cells to TMZ. Mechanistically, PPF decreased glioma cell invasion by modulating TROY expression and downstream signaling, including AKT, NF-κB, and Rac1 activation. Thus, PPF may provide a pharmacologic approach to target TROY, inhibit cell invasion, and reduce therapeutic resistance in GBM.

Original languageEnglish (US)
Pages (from-to)397-404
Number of pages8
JournalJournal of Neuro-Oncology
Volume126
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

Glioblastoma
Cell Survival
temozolomide
Glioma
Alzheimer Disease
propentofylline
Phase III Clinical Trials
Vascular Dementia
Survival
Heterografts
Permeability
Neoplasms
Therapeutics
Recurrence
Brain

Keywords

  • Glioblastoma
  • Invasion
  • Resistance
  • Survival
  • TROY

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway. / Dhruv, Harshil D.; Roos, Alison; Tomboc, Patrick J.; Tuncali, Serdar; Chavez, Ashley; Mathews, Ian; Berens, Michael E.; Loftus, Joseph C; Tran, Nhan.

In: Journal of Neuro-Oncology, Vol. 126, No. 3, 01.02.2016, p. 397-404.

Research output: Contribution to journalArticle

Dhruv, Harshil D. ; Roos, Alison ; Tomboc, Patrick J. ; Tuncali, Serdar ; Chavez, Ashley ; Mathews, Ian ; Berens, Michael E. ; Loftus, Joseph C ; Tran, Nhan. / Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway. In: Journal of Neuro-Oncology. 2016 ; Vol. 126, No. 3. pp. 397-404.
@article{8a53cf8558f64fe49676277b9d390929,
title = "Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway",
abstract = "Glioblastoma (GBM) is the most common primary tumor of the CNS and carries a dismal prognosis. The aggressive invasion of GBM cells into the surrounding normal brain makes complete resection impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Median survival for newly diagnosed GBM is 14.6 months and declines to 8 months for patients with recurrent GBM. New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome. We have demonstrated that TROY (TNFRSF19), a member of the TNFR super-family, plays an important role in GBM invasion and resistance. Knockdown of TROY expression inhibits GBM cell invasion, increases sensitivity to temozolomide, and prolongs survival in an intracranial xenograft model. Propentofylline (PPF), an atypical synthetic methylxanthine compound, has been extensively studied in Phase II and Phase III clinical trials for Alzheimer’s disease and vascular dementia where it has demonstrated blood–brain permeability and minimal adverse side effects. Here we showed that PPF decreased GBM cell expression of TROY, inhibited glioma cell invasion, and sensitized GBM cells to TMZ. Mechanistically, PPF decreased glioma cell invasion by modulating TROY expression and downstream signaling, including AKT, NF-κB, and Rac1 activation. Thus, PPF may provide a pharmacologic approach to target TROY, inhibit cell invasion, and reduce therapeutic resistance in GBM.",
keywords = "Glioblastoma, Invasion, Resistance, Survival, TROY",
author = "Dhruv, {Harshil D.} and Alison Roos and Tomboc, {Patrick J.} and Serdar Tuncali and Ashley Chavez and Ian Mathews and Berens, {Michael E.} and Loftus, {Joseph C} and Nhan Tran",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s11060-015-1981-0",
language = "English (US)",
volume = "126",
pages = "397--404",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway

AU - Dhruv, Harshil D.

AU - Roos, Alison

AU - Tomboc, Patrick J.

AU - Tuncali, Serdar

AU - Chavez, Ashley

AU - Mathews, Ian

AU - Berens, Michael E.

AU - Loftus, Joseph C

AU - Tran, Nhan

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Glioblastoma (GBM) is the most common primary tumor of the CNS and carries a dismal prognosis. The aggressive invasion of GBM cells into the surrounding normal brain makes complete resection impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Median survival for newly diagnosed GBM is 14.6 months and declines to 8 months for patients with recurrent GBM. New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome. We have demonstrated that TROY (TNFRSF19), a member of the TNFR super-family, plays an important role in GBM invasion and resistance. Knockdown of TROY expression inhibits GBM cell invasion, increases sensitivity to temozolomide, and prolongs survival in an intracranial xenograft model. Propentofylline (PPF), an atypical synthetic methylxanthine compound, has been extensively studied in Phase II and Phase III clinical trials for Alzheimer’s disease and vascular dementia where it has demonstrated blood–brain permeability and minimal adverse side effects. Here we showed that PPF decreased GBM cell expression of TROY, inhibited glioma cell invasion, and sensitized GBM cells to TMZ. Mechanistically, PPF decreased glioma cell invasion by modulating TROY expression and downstream signaling, including AKT, NF-κB, and Rac1 activation. Thus, PPF may provide a pharmacologic approach to target TROY, inhibit cell invasion, and reduce therapeutic resistance in GBM.

AB - Glioblastoma (GBM) is the most common primary tumor of the CNS and carries a dismal prognosis. The aggressive invasion of GBM cells into the surrounding normal brain makes complete resection impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Median survival for newly diagnosed GBM is 14.6 months and declines to 8 months for patients with recurrent GBM. New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome. We have demonstrated that TROY (TNFRSF19), a member of the TNFR super-family, plays an important role in GBM invasion and resistance. Knockdown of TROY expression inhibits GBM cell invasion, increases sensitivity to temozolomide, and prolongs survival in an intracranial xenograft model. Propentofylline (PPF), an atypical synthetic methylxanthine compound, has been extensively studied in Phase II and Phase III clinical trials for Alzheimer’s disease and vascular dementia where it has demonstrated blood–brain permeability and minimal adverse side effects. Here we showed that PPF decreased GBM cell expression of TROY, inhibited glioma cell invasion, and sensitized GBM cells to TMZ. Mechanistically, PPF decreased glioma cell invasion by modulating TROY expression and downstream signaling, including AKT, NF-κB, and Rac1 activation. Thus, PPF may provide a pharmacologic approach to target TROY, inhibit cell invasion, and reduce therapeutic resistance in GBM.

KW - Glioblastoma

KW - Invasion

KW - Resistance

KW - Survival

KW - TROY

UR - http://www.scopus.com/inward/record.url?scp=84956665655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956665655&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1981-0

DO - 10.1007/s11060-015-1981-0

M3 - Article

C2 - 26559543

AN - SCOPUS:84956665655

VL - 126

SP - 397

EP - 404

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -